A Systematic Review of Cost Effectiveness of Pembrolizumab Versus Standard Treatment for Metastatic Non-Small Cell Lung Cancer
Penulis/Author
FITRIANA YULIASTUTI (1); Prof. Dr. Susi Ari Kristina, S.Farm., M.Kes., Apt. (2); Dr. apt. Dwi Endarti, S.F., M.Sc. (3); Prof. Dr. Tri Murti Andayani, Sp.FRS., Apt. (4)
Tanggal/Date
2021
Kata Kunci/Keyword
Abstrak/Abstract
Background: This study aimed to review the available literature on the cost-effectiveness of pembrolizumab versus standard chemotherapy treatment as first-line treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) with Programmed Death Ligand-1 (PD-L1) from multiple paying perspectives.
Methods: A systematic review was conducted to identify related studies. Electronic databases used to identify relevant studies are, ScienceDirect, Cochrane and PubMed. This study is limited to English and publications from 2015 to 2020. Study characteristics and result were recorded and compared.
Results: An electronic database search yield 35 articles while only 7 studies met the criteria for review. The most widely used method in this research, includes modeling, sensitivity analysis as well as cost-effectiveness analysis were carried out. All studies were evaluated directly cost and used quality-adjusted life years (QALY) and years of life earned, at a discount rate of 3% and 4%. pembrolizumab compared with chemotherapy in a population with PD-L1 TPS ?50% ICER US $ US97,621/ QALY; Hongkong $ 110,922/QALY; USA $ US130,155; Switzerland $100,000; France $ US96,050.38; China $ 36,493; China $ 136,228.82. The QHES tool was used to confirm the
quality of existing studies and showed that the score was 89.14.
Conclusion: This literature study suggests that pembrolizumab is a project to be a cost-effective option compared to platinum-based Standard of Care (SoC) chemotherapy as the first-line treatment in adults with metastatic nonsmall cell lung cancer (NSCLC) programmed death ligand-1 (PD-L1).
Rumpun Ilmu
Farmasi Umum dan Apoteker
Bahasa Asli/Original Language
English
Level
Internasional
Status
Dokumen Karya
No
Judul
Tipe Dokumen
Aksi
1
ijpr economic lung cancer.pdf
[PAK] Bukti Korespondensi Penulis
2
A Systematic Review of Cost Effectiveness of Pembrolizumab Versus Standard Treatment for Metastatic Non-Small Cell Lung Cancer (1).pdf
